Algert Global’s Dianthus Therapeutics DNTH Stock Holding History

Algert Global’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.02M	Sell	20,690 -23,708	-53%	-$2.07M	0.02%	829
2026 Q1	$3.73M	Sell	44,398 -85,928	-66%	-$4.98M	0.06%	526
2025 Q4	$5.37M	Buy	+130,326	New	+$5.05M	0.08%	408
2021 Q4	–	Sell	-939	Closed	-$109K	–	1001
2021 Q3	$109K	Sell	939 -558	-37%	-$65K	0.01%	960
2021 Q2	$234K	Sell	1,497 -1,177	-44%	-$216K	0.08%	330
2021 Q1	$507K	Buy	2,674 +350	+15%	+$58.9K	0.16%	201
2020 Q4	$291K	Sell	2,324 -617	-21%	-$70K	0.08%	301
2020 Q3	$320K	Buy	2,941 +2,210	+302%	+$262K	0.1%	245
2020 Q2	$88K	Buy	+731	New	+$103K	0.03%	380
2019 Q4	–	Sell	-784	Closed	-$129K	–	398
2019 Q3	$129K	Buy	+784	New	+$149K	0.05%	310

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Algert Global's DNTH Position: Q2 2026 in Review

Algert Global reduced its Dianthus Therapeutics (DNTH) stake by 53% in Q2 2026, selling an estimated $2.07M and leaving 20,690 shares worth $2.02M. The position accounts for 0.02% of the portfolio, ranked #829.

Algert Global first reported a position in DNTH in Q3 2019 and has held it in 10 quarters since. The position peaked at $5.37M in Q4 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Algert Global held 20,690 shares of Dianthus Therapeutics worth $2.02M as of Q2 2026.
Algert Global sold 23,708 Dianthus Therapeutics shares in Q2 2026, an estimated $2.07M.
Dianthus Therapeutics made up 0.02% of Algert Global's portfolio in Q2 2026, its #829 holding.
Algert Global first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 10 quarters since.
Algert Global's Dianthus Therapeutics position peaked at $5.37M in Q4 2025.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.